A pan­el of out­side ad­vi­sors to the FDA vot­ed 11-5 in fa­vor of Zevra Ther­a­peu­tics’ drug for a rare ge­net­ic ...

Eli Lilly's blockbuster weight loss and diabetes drugs are no longer in shortage, according to the FDA's database that tracks ...

Massachusetts Gov. Maura Healey’s proposal to invest another $1 billion in life sciences over the next 10 years has been ...

Devoted Health just nabbed another $112 million in venture funding to fuel its push into seven new states, Endpoints News has ...

The FDA granted accelerated approval to a cell therapy for synovial sarcoma, a rare type of cancer typically found in the ...

Rare disease specialist Ultragenyx reeled in a $14 million seed round for its Alzheimer’s gene therapy spinout Amlogenyx, the ...

Ken Song is back in business. He left RayzeBio in February after leading the radiopharmaceuticals startup from Series A to ...

Biogen and Eisai's Alzheimer's drug Leqembi is off to a slow start in the US. But it's big in Japan. On Friday, Eisai ...

Kyowa Kirin is selling off its China business and transitioning to a research organization in a shake-up that could lead to ...

CEO Anne Wojcicki’s offer to take her genetic testing company 23andMe private for 40 cents a share has been met with ...

Ribon Therapeutics has shuttered after nine years, and one year after ending its preclinical research to focus on two ...

Agios’ first-ever pediatric data readout missed the primary endpoint, with its drug Pyrukynd (mitapivat) not showing ...